SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201
2 references·16 citing·45 second hop
Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201 (2008)Comparison of the analytical and operatio…Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT) (2005)Trends in risk of transfusion…Multicenter performance evaluation of a transcription‐mediated amplification assay for screening of human immunodeficiency virus‐1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations (2005)Multicenter performance evalu…The impact of nucleic acid testing to detect human immunodeficiency virus, hepatitis C virus, and hepatitis B virus yields from a single blood center in China with 10-years review (2022)The impact of nucleic acid te…Transfusion of HIV‐infected blood products despite highly sensitive nucleic acid testing (2019)Transfusion of HIV‐infected b…The Brazilian experience of nucleic acid testing to detect human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in blood donors (2018)The Brazilian experience of n…The current status of nucleic acid amplification technology in transfusion‐transmitted infectious disease testing (2016)The current status of nucleic…Comparison of Procleix Ultrio Elite and Procleix Ultrio NAT Assays for Screening of Transfusion Transmitted Infections among Blood Donors in India (2016)Comparison of Procleix Ultrio…Automated Triplex (HBV, HCV and HIV) NAT Assay Systems for Blood Screening in India (2016)Automated Triplex (HBV, HCV a…NAT yield for human immunodeficiency and hepatitis C viruses in Brazilian blood donors: preliminary results (2015)NAT yield for human immunodef…Automation in Blood Centre: Its impact on Blood Safety (2015)Automation in Blood Centre: I…The rates, perceptions, and willingness of men who have sex with men to donate blood (2014)The rates, perceptions, and w…Nucleic A cid T echnology ( NAT ) testing for blood screening: impact of individual donation and M ini P ool – NAT testing on analytical sensitivity, screening sensitivity and clinical sensitivity (2014)Nucleic A cid T echnology ( N…Factors in enhancing blood safety by nucleic acid technology testing for human immunodeficiency virus, hepatitis C virus and hepatitis B virus (2014)Factors in enhancing blood sa…Molecular virology in transfusion medicine laboratory. (2013)Molecular virology in transfu…Evaluation of two, commercial, multi‐dye, nucleic acid amplification technology tests, for HBV/HCV/HIV‐1/HIV‐2 and B19V/HAV, for screening blood and plasma for further manufacture (2012)Evaluation of two, commercial…Évolutions technologiques en qualification biologique du don et leur impact sur le risque résiduel transfusionnel (2011)Évolutions technologiques en …One‐year experience of nucleic acid technology testing for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus in Thai blood donations (2009)One‐year experience of nuclei…Blood donor screening with cobas s 201/cobas TaqScreen MPX under routine conditions at German Red Cross institutes (2009)Blood donor screening with co…The Cambridge Ancient History (1971)The Risk of Transfusion-Transmitted Viral Infections (1996)International application of the Incidence Rate/Window Period model (2002)Evaluation of a new molecular assay for detection of human immunodeficiency virus type 1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA (2006)Evaluation of a multiplex human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand (2007)HIV-1, HCV and HBV seronegative window reduction by the new Roche cobas® TaqScreen MPX test in seroconverting donors (2007)Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting (1999)Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid–Amplification Testing (2004)Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus (2008)Comparison of HIV-1 detection in plasma specimens and dried blood spots using the Roche COBAS Ampliscreen HIV-1 test in Kisumu, Kenya (2011)Nucleic acid testing: Is it the only answer for safe Blood in India? (2016)Yield of HCV and HIV‐1 NAT after screening of 3.6 million blood donations in central Europe (2002)International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009 (2011)The prevalence of hepatitis A virus and parvovirus B19 in source‐plasma donors and whole blood donors in China (2015)Anti‐ HB c screening – is it worth the effort? Results of a 10‐year surveillance programme covering more than 30 million donations in Germany (2019)The cost‐effectiveness of NAT for HIV, HCV, and HBV in whole‐blood donations (2003)Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing (2010)Racial and Sexual Identity-Related Maltreatment Among Minority YMSM: Prevalence, Perceptions, and the Association with Emotional Distress (2011)Eligibility and willingness to donate blood in men who have (had) sex with men (2017)Blood donation history and eligibility assessment in a community‐based sample of men who have sex with men (2018)Attitudes and willingness to donate blood among gay and bisexual men in Australia (2020)Infectivity of human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion (2009)Cost effectiveness of adding nucleic acid testing to hepatitis B , hepatitis C , and human immunodeficiency virus screening of blood donations in Z imbabwe (2016)NAT positivity in seronegative voluntary blood donors from western India (2016)Hepatitis B virus blood screening: unfinished agendas (2006)BLOOD DONORS AND BLOOD COLLECTION: Web interface–supported transmission risk assessment and cost‐effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands (2009)Nucleic acid testing (NAT) in high prevalence–low resource settings (2010)Reduction of the risk of transfusion‐transmitted viral infection by nucleic acid amplification testing in the Western Cape of South Africa: a 5‐year review (2012)Current incidence and estimated residual risk of transfusion‐transmitted infections in donations made to Canadian Blood Services (2007)Detection of HIV-1 infections in blood donors during the pre-seroconversion window period in São Paulo, Brazil (2019)10‐year analysis of human immunodeficiency virus incidence in first‐time and repeat donors in Brazil (2020)Quality and safety measures in transfusion practice: The experience of eight southern/eastern Mediterranean countries (2020)Donor Testing and Risk: Current Prevalence, Incidence, and Residual Risk of Transfusion-Transmissible Agents in US Allogeneic Donations (2011)High rate of hepatitis C virus and human immunodeficiency virus false‐positive results in serologic screening in sub‐Saharan Africa: adverse impact on the blood supply (2019)An international comparison of HIV prevalence and incidence in blood donors and general population: a BEST Collaborative study (2021)Efficacy of Different Testing Scenarios in Reducing Transfusion-Transmitted Hepatitis B Virus (TT-HBV) Infection Risk (2022)A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors (2005)Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6‐year survey (2008)Prevalence and Trends of Transfusion-Transmissible Viral Infections among Blood Donors in South of Iran: An Eleven-Year Retrospective Study (2016)Demographic Factors Among HIV Confirmed Blood Donors from 2013 to 2021 in Shenzhen (2023)Effectiveness of Using Nucleic Acid Amplification Test to Screen Blood Donors for Hepatitis B, Hepatitis C, and HIV: A Tertiary Care Hospital Experience From Pakistan (2023)A comparative analysis between NAT and chemiluminescence in detection of transfusion transmitted viruses in two main university blood transfusion centers (2025)Residual risk of transfusion‐transmitted viral infections in Shenzhen, China, 2001 through 2004 (2007)Nucleic acid amplification testing in Indian blood banks: A review with perspectives (2017)Prevalence, incidence and residual risk of transfusion-transmitted hepatitis C virus and human immunodeficiency virus after the implementation of nucleic acid testing in Italy: a 7-year (2009-2015) survey. (2018)
this work references cited by second hop

References

  • 2005Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT)96 cited
  • 2005Multicenter performance evaluation of a transcription‐mediated amplification assay for screening of human immunodeficiency virus‐1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations56 cited

Cited by

  • 2009One‐year experience of nucleic acid technology testing for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus in Thai blood donations48 cited
  • 2012Evaluation of two, commercial, multi‐dye, nucleic acid amplification technology tests, for HBV/HCV/HIV‐1/HIV‐2 and B19V/HAV, for screening blood and plasma for further manufacture27 cited
  • 2009Blood donor screening with cobas s 201/cobas TaqScreen MPX under routine conditions at German Red Cross institutes22 cited
  • 2019Transfusion of HIV‐infected blood products despite highly sensitive nucleic acid testing22 cited
  • 2014The rates, perceptions, and willingness of men who have sex with men to donate blood22 cited
  • 2022The impact of nucleic acid testing to detect human immunodeficiency virus, hepatitis C virus, and hepatitis B virus yields from a single blood center in China with 10-years review20 cited
  • 2014Factors in enhancing blood safety by nucleic acid technology testing for human immunodeficiency virus, hepatitis C virus and hepatitis B virus17 cited
  • 2018The Brazilian experience of nucleic acid testing to detect human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in blood donors17 cited
  • 2014Nucleic A cid T echnology ( NAT ) testing for blood screening: impact of individual donation and M ini P ool – NAT testing on analytical sensitivity, screening sensitivity and clinical sensitivity

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

16 cited
  • 2013Molecular virology in transfusion medicine laboratory.15 cited
  • 2016Comparison of Procleix Ultrio Elite and Procleix Ultrio NAT Assays for Screening of Transfusion Transmitted Infections among Blood Donors in India15 cited
  • 2015Automation in Blood Centre: Its impact on Blood Safety14 cited
  • 2011Évolutions technologiques en qualification biologique du don et leur impact sur le risque résiduel transfusionnel10 cited
  • 2016The current status of nucleic acid amplification technology in transfusion‐transmitted infectious disease testing8 cited
  • 2015NAT yield for human immunodeficiency and hepatitis C viruses in Brazilian blood donors: preliminary results7 cited
  • 2016Automated Triplex (HBV, HCV and HIV) NAT Assay Systems for Blood Screening in India7 cited